Casebia Therapeutics Revenue and Competitors

Claim your profile

Boston, MA USA

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Casebia Therapeutics's estimated annual revenue is currently $930k per year.(i)
  • Casebia Therapeutics's estimated revenue per employee is $155,000

Employee Data

  • Casebia Therapeutics has 6 Employees.(i)
  • Casebia Therapeutics grew their employee count by -40% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0.2M1-99%N/AN/A
#2
$3.1M20233%N/AN/A
#3
$21.5M13918%$351MN/A
#4
$18M1165%$312.8MN/A
#5
$235M418-23%$340.9MN/A
#6
$2.2M3417%N/AN/A
#7
$6M40-9%$176.5MN/A
#8
$109.4M70614%N/AN/A
#9
$6.2M40233%N/AN/A
#10
$1.9M12-20%N/AN/A

Bayer and CRISPR Therapeutics have entered into an agreement to create Casebia to discover, develop and commercialize new breakthrough therapeutics to cure blood disorders, blindness, and congenital heart disease. CRISPR Therapeutics will contribute its proprietary CRISPR-Cas9 gene-editing technology and intellectual property, while Bayer will make available its protein engineering expertise and relevant disease know-how. It is the first long-term strategic partnership of its kind to make a substantial investment in the development of target delivery systems in an effort to bring systemic in vivo CRISPR-Cas9 gene editing technology applications to patients.

keywords:N/A

N/A

Total Funding

6

Number of Employees

$930k

Revenue (est)

-40%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Casebia Therapeutics News

2022-04-17 - Movers & Shakers: John Maraganore, Larry Alstiel, Brad ...

Before 7joining Exo Therapeutics, Schneider was SVP of finance at Casebia Therapeutics, LLC. Before Casebia, he held senior finance...

2022-04-17 - Freeline Appoints Paul Schneider as Chief Financial Officer

Schneider was Senior Vice President, Finance at Casebia Therapeutics, LLC. Before joining Casebia, he held senior finance positions at Aegerion...

2022-04-17 - Tessera Therapeutics stacks up more than $300M in series C ...

Prior to joining Exo in 2020, he was SVP of finance at Casebia Therapeutics. Release. Evidence of its commitment to clinical progress,...

2019-09-03 - Bayer nabs new dealmaker—but after Monsanto, is there ...

... with small startups, including its 2016 Casebia Therapeutics, formed by Bayer and CRISPR Therapeutics, which aims to cure blood disorders ...

2019-08-27 - Gene editing companies oppose altering of embryos

Thirteen biopharma companies, including Sangamo Therapeutics and ... James Burns, CEO of Casebia Therapeutics, one of the co-signers, ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
N/A650%N/A
#2
$0.1M650%N/A
#3
$0.9M6N/AN/A
#4
$0.4M6N/AN/A
#5
$0.4M6N/AN/A